The company said it made the switch to the new name and logo, which features a thumb-print combined with circuity, as a representation of the connection between surgeon and technology that the robotic system provides.
“We are pleased to announce the new brand identity for our multiport surgical robotic system. This is a pivotal point in our growth strategy and we believe Senhance speaks directly to the benefits experienced with our system. Our goal is to advance minimally invasive surgery and the tools surgeons have at their disposal to provide patients with the best possible care while also providing a more attractive value proposition to the hospital. Senhance is designed to enhance laparoscopic surgery and specifically empowers the senses of the surgeon in ways that were never previously possible. The security of haptics and the convenience of eye sensing camera control are meaningful ways that technology can provide a further extension of the surgeon’s skill,” CEO Todd Pope said in prepared remarks.
The company acquired the Telelap ALF-X robot-assisted surgery device from Italy’s Sofar SpA last September. The Telelap ALF-X device has CE Mark approval in the European Union for minimally invasive surgery procedures.
The Morrisville, N.C.-based company sold its 1st ALF-X system in August to Milan, Italy’s Humanitas Hospital.
TransEnterix shelved its SurgiBot robot-assisted surgery device earlier this year after the FDA denied its submission for 510(k) clearance for the SurgiBot, which it claims as the 1st patient-side robotically enhanced laparoscopy platform designed to be wheeled to a patient’s bedside for single-port procedures.
In May, company executives, saying they think getting SurgiBot through the FDA would require another 510(k) submission, said they’re cutting their losses on the project and turning to the ALF-X device. TransEnterix last fall put nearly $100 million on the table for Italy’s Sofar, which developed the Telelap ALF-X and took it through CE Mark approval in the European Union.